Exelixis, Inc. (NASDAQ: EXEL) today announced it has completed the submission of a supplemental New Drug Application (sNDA) to the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE